These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932 [TBL] [Abstract][Full Text] [Related]
6. QM/MM Simulations of Afatinib-EGFR Addition: The Role of β-Dimethylaminomethyl Substitution. Ma S; Patel H; Peeples CA; Shen J J Chem Theory Comput; 2024 Jul; 20(13):5528-5538. PubMed ID: 38877999 [TBL] [Abstract][Full Text] [Related]
7. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib. Callegari D; Ranaghan KE; Woods CJ; Minari R; Tiseo M; Mor M; Mulholland AJ; Lodola A Chem Sci; 2018 Mar; 9(10):2740-2749. PubMed ID: 29732058 [TBL] [Abstract][Full Text] [Related]
8. QM/MM modelling of ketosteroid isomerase reactivity indicates that active site closure is integral to catalysis. van der Kamp MW; Chaudret R; Mulholland AJ FEBS J; 2013 Jul; 280(13):3120-31. PubMed ID: 23356661 [TBL] [Abstract][Full Text] [Related]
9. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Engel J; Richters A; Getlik M; Tomassi S; Keul M; Termathe M; Lategahn J; Becker C; Mayer-Wrangowski S; Grütter C; Uhlenbrock N; Krüll J; Schaumann N; Eppmann S; Kibies P; Hoffgaard F; Heil J; Menninger S; Ortiz-Cuaran S; Heuckmann JM; Tinnefeld V; Zahedi RP; Sos ML; Schultz-Fademrecht C; Thomas RK; Kast SM; Rauh D J Med Chem; 2015 Sep; 58(17):6844-63. PubMed ID: 26275028 [TBL] [Abstract][Full Text] [Related]
10. Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Vacondio F; Carmi C; Galvani E; Bassi M; Silva C; Lodola A; Rivara S; Cavazzoni A; Alfieri RR; Petronini PG; Mor M Bioorg Med Chem Lett; 2013 Oct; 23(19):5290-4. PubMed ID: 23988354 [TBL] [Abstract][Full Text] [Related]
11. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531 [TBL] [Abstract][Full Text] [Related]
13. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases. Huang Y; Rizzo RC Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796 [TBL] [Abstract][Full Text] [Related]
14. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635 [TBL] [Abstract][Full Text] [Related]
15. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192 [TBL] [Abstract][Full Text] [Related]
16. Homology models of the mutated EGFR and their response towards quinazoline analogues. Kotra S; Madala KK; Jamil K J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943 [TBL] [Abstract][Full Text] [Related]
17. QM/MM simulations of EFGR with afatinib reveal the role of the Ma S; Patel H; Peeples CA; Shen J bioRxiv; 2024 May; ():. PubMed ID: 38766221 [TBL] [Abstract][Full Text] [Related]
18. QM/MM simulations of amyloid-β 42 degradation by IDE in the presence and absence of ATP. da Cruz CH; Seabra GM J Chem Inf Model; 2015 Jan; 55(1):72-83. PubMed ID: 25539133 [TBL] [Abstract][Full Text] [Related]
19. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369 [TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]